Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERILE WATER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Water serves as a solvent and vehicle for drug administration; it has no intrinsic pharmacological activity.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
Reconstitution of powdered medications,Dilution of intravenous medications,Flushing of intravenous lines,Hydration (when combined with electrolytes)
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
50-100 m L intravenous bolus as a vehicle for drug reconstitution or for hydration; frequency as needed for specific clinical indication.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
1.5–3.5 hours; water turnover depends on physiological state; clinical context: equilibrates rapidly with total body water
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
Not metabolized; excreted unchanged primarily by the kidneys.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Renal: >99% as water; fecal: negligible; biliary: negligible
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
0% (water is not protein-bound)
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
0.6 L/kg (approximates total body water; Vd ~42 L in 70 kg adult)
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
Intravenous: 100%; Oral: >95% (essentially complete absorption)
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
No dose adjustment required; however, careful monitoring of fluid balance in patients with renal impairment to avoid fluid overload.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
No dose adjustment required; sterile water does not undergo hepatic metabolism.
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
Dose based on patient weight and clinical need; typical fluid maintenance: 100 m L/kg/day for first 10 kg, plus 50 m L/kg/day for next 10 kg, plus 20 m L/kg/day for weight above 20 kg; administered intravenously.
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
Use with caution due to potential for fluid overload; adjust volume based on renal function and cardiovascular status; typical starting dose 25-50 m L intravenous bolus.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
None.
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
Use only sterile water for injection; hypotension and electrolyte disturbances if used in large volumes without electrolytes; hemolysis if administered intravenously without isotonicity.
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
Hypersensitivity to any component; do not use for intravenous injection without first making isotonic by adding solutes (except for reconstitution followed by dilution).
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
No known food interactions.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
No known teratogenic effects in any trimester; sterile water is not pharmacologically active and does not cross the placenta in quantities that would produce fetal effects. Risk classification: FDA Category A (if considered a drug) or generally recognized as safe.
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
Compatible with breastfeeding; water is a normal constituent of breast milk and maternal administration does not increase risk. M/P ratio: 1.0 (approximate, as water distributes equally in body fluids).
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
No dose adjustment required; pharmacokinetics of water are unchanged in pregnancy. Standard dosing based on clinical need (e.g., hydration, dilution of medications).
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
Sterile water is used for dilution or reconstitution of medications before injection. It is not for direct intravenous administration without tonicity adjustment. Use within 2 hours after opening to minimize contamination risk.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
This product is not for direct injection; it must be mixed with medication by a healthcare professional.,Do not use if solution is cloudy or contains particulates.,Store at room temperature away from moisture and heat.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERILE WATER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
STERILE WATER is a Irrigation Solution that works by Water serves as a solvent and vehicle for drug administration; it has no intrinsic pharmacological activity.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERILE WATER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERILE WATER is: 50-100 m L intravenous bolus as a vehicle for drug reconstitution or for hydration; frequency as needed for specific clinical indication.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERILE WATER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERILE WATER is classified as Category C. No known teratogenic effects in any trimester; sterile water is not pharmacologically active and does not cross the placenta in quantities that would produce fetal effects. Risk cl. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.